NY-SK-CAPITAL-PARTNERS
16.2.2021 08:02:11 CET | Business Wire | Press release
SK Capital Partners, LP, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, today announced it will be expanding its team with the addition of Daniele Ferrari as Senior Director.
Mr. Ferrari brings over 35 years of direct operating and executive experience in the chemicals industry, most recently serving as the CEO of Versalis S.p.A., one of Europe’s largest chemicals companies, and as Chairman of Matrìca S.p.A., a joint-venture with Novamont, a leader in the bio-plastics industry at the forefront of the renewable chemistry sector. At Versalis S.p.A., Mr. Ferrari led the company’s efforts to reposition downstream and grow the company’s portfolio of higher margin, specialty and renewable chemical products, including creating the company’s BioTech global business unit. Mr. Ferrari started his career at Agip Petroli, a subsidiary of Eni S.p.A., and Imperial Chemical Industries (ICI), before joining Huntsman in 1997, where he held numerous roles and international assignments spanning his 14 year tenure, during which he ultimately became the global President of Huntsman’s Performance Products division.
Mr. Ferrari also brings significant leadership in the area of sustainability, promoting processes that support a more circular economy and the development and usage of renewable chemical solutions. He was the immediate past President of the European Chemical Industry Council (CEFIC), which is the largest trade association for the chemical industry in Europe. He previously served as President of PlasticsEurope Bruxelles, the association of European plastics manufacturers, and as a board member of Alliance to End Plastics Waste.
Mr. Ferrari has an Industrial Chemical background and was awarded an Honorary Master’s degree in Chemical Sciences from the University of Ferrara. He currently serves as a director on the boards of Huntsman Corporation (NYSE: HUN) and Venator Materials PLC (NYSE: VNTR), where he chairs the Audit Committee. Mr. Ferrari also serves on the board of the Oxford University Business Economics Program.
Barry Siadat, Co-Founder and Managing Director at SK Capital, commented, "Daniele brings an unparalleled level of operating and executive leadership experience to the firm. He has successfully led multiple companies within the chemical industry for decades and shares a strong passion for sustainability." Siadat added, "Daniele’s deep knowledge of and experience in our sectors of focus make him an ideal match for his new position at SK Capital."
"SK Capital is well-known in the industry for leveraging its operating and investing expertise to drive business transformation and improvement," said Mr. Ferrari. "I am delighted to join the SK Capital team and look forward to supporting the firm's ongoing growth and success."
Jamshid Keynejad, Co-Founder and Managing Director at SK Capital, commented, “Daniele is a proven leader in our industry who brings a unique skillset and decades of operating experience to SK Capital. We are excited to add him to our team and we look forward to working together to enhance the value of our portfolio and support the growth of our firm.”
ABOUT SK CAPITAL
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $11 billion annually, employs more than 15,000 people globally and operates 137 plants in 28 countries. The firm currently has approximately $4.86 billion of assets under management. For more information, please visit www.skcapitalpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210215005389/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom